Hatteras Venture Partners has successfully raised $200 million across two funds dedicated to early-stage investments in life sciences.
Why it matters: The successful raise by Hatteras could signal a shift in investor sentiment, suggesting a strong appetite for high-potential early-stage companies, even amidst economic uncertainty.
The details:
- The funds, Hatteras’ seventh venture fund and the Hatteras Opportunity Fund I, are poised to support emerging biotechs, medtech, and healthcare companies.
- The North Carolina-based firm, celebrating its 25th anniversary, also marked a milestone of investing in its one-hundredth company.
- Over the past quarter-century, Hatteras has raised over $900 million across seven VC funds.
- The firm focuses on seed- and early-stage companies in the health innovation sectors, spanning biotech, medtech, and healthtech.
Hatteras continues to leverage its deep expertise and network, providing crucial support and funding to companies poised for growth.
What they’re saying:
- “Across 100 portfolio companies and 25 years, we’ve experienced exhilarating wins along with heartbreaking disappointments. What has been most gratifying in this journey is the relationships we have made with scholarly innovators, committed entrepreneurs, and resilient co-investors. We look forward to continuing to invest in transformative life sciences companies disrupting the status quo in healthcare and accelerating the pace of innovation.” – Clay Thorp, General Partner of Hatteras
- “Ben and Lauren possess the values, instincts, and tenacity we need to lead Hatteras into the future. The opportunity for them to lead new deals and harvest existing investments in HVP VII is tremendous, and I look forward to continuing our work together as they step into these expanded leadership roles.” – John Crumpler, Co-Founder and General Partner of Hatteras
What’s next: As the investment community watches closely, the success of Hatteras’s fundraising efforts could inspire other firms to follow suit, potentially leading to a broader revival of mega-round funding in the latter half of the year.